0 497

Cited 27 times in

The promise of bispecific antibodies: Clinical applications and challenges

DC Field Value Language
dc.contributor.author임선민-
dc.contributor.author조병철-
dc.contributor.author표경호-
dc.date.accessioned2021-09-29T01:52:03Z-
dc.date.available2021-09-29T01:52:03Z-
dc.date.issued2021-09-
dc.identifier.issn0305-7372-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/184588-
dc.description.abstractThe development of cancer therapies using monoclonal antibodies has been successful during the last 30 years. Recently much progress was achieved with technologies involving bispecific and multi-specific antibodies. Bispecific antibodies (BsAbs) are antibodies that bind two distinct epitopes, and a large number of potential clinical applications of BsAbs have been described. Here we review mechanism of action, clinical development and future challenges of BsAbs which could be a serve as a valuable arsenal in cancer patients.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier-
dc.relation.isPartOfCANCER TREATMENT REVIEWS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntibodies, Bispecific / immunology-
dc.subject.MESHAntibodies, Bispecific / therapeutic use*-
dc.subject.MESHAntineoplastic Agents, Immunological / therapeutic use-
dc.subject.MESHClinical Trials, Phase I as Topic-
dc.subject.MESHClinical Trials, Phase II as Topic-
dc.subject.MESHClinical Trials, Phase III as Topic-
dc.subject.MESHHumans-
dc.subject.MESHImmune Checkpoint Inhibitors / therapeutic use-
dc.subject.MESHNeoplasms / immunology*-
dc.subject.MESHNeoplasms / therapy*-
dc.subject.MESHRandomized Controlled Trials as Topic-
dc.titleThe promise of bispecific antibodies: Clinical applications and challenges-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSun Min Lim-
dc.contributor.googleauthorKyoung-Ho Pyo-
dc.contributor.googleauthorRoss A Soo-
dc.contributor.googleauthorByoung Chul Cho-
dc.identifier.doi10.1016/j.ctrv.2021.102240-
dc.contributor.localIdA03369-
dc.contributor.localIdA03822-
dc.contributor.localIdA04809-
dc.relation.journalcodeJ04106-
dc.identifier.eissn1532-1967-
dc.identifier.pmid34119803-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0305737221000888-
dc.subject.keywordBispecific antibodies-
dc.subject.keywordCancer-
dc.contributor.alternativeNameLim, Sun Min-
dc.contributor.affiliatedAuthor임선민-
dc.contributor.affiliatedAuthor조병철-
dc.contributor.affiliatedAuthor표경호-
dc.citation.volume99-
dc.citation.startPage102240-
dc.identifier.bibliographicCitationCANCER TREATMENT REVIEWS, Vol.99 : 102240, 2021-09-
Appears in Collections:
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.